Tirzepatide, after the hype.
Nine months, four women, one drug — and the uncomfortable parts of the GLP-1 boom that rarely make it into glossy before-and-afters.
Tirzepatide deserves the attention. In large trials, the weight-loss signal is materially stronger than first-generation GLP-1 monotherapy, and the metabolic secondary endpoints are difficult to dismiss.
But the consumer internet has flattened a clinical intervention into a lifestyle aesthetic. The actual story is less glamorous: dosing tolerance, lean-mass preservation, cost, access, discontinuation rebound, and the need for long-term monitoring.
What held up
The efficacy data is consistent enough to grade highly. The strongest case is not a single transformation photo; it is a pattern across randomized studies, improved glycemic markers, and durability while treatment continues.
What still needs caution
GI burden remains common, muscle retention needs active management, and stopping therapy is not a neutral event for many patients. Talk to a clinician who understands the tradeoffs before treating this as a shortcut.